Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Position statement: The need for EU legislation to require disclosure and labelling of the composition of medical devices

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Metronidazole for Hidradenitis Suppurativa: future potential treatment applications

    Publikation: Bidrag til tidsskriftLetterpeer review

  2. Clinical characteristics including cardiovascular and metabolic risk factors in adolescents with psoriasis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Obesity as a risk factor for psoriasis

    Publikation: Bidrag til tidsskriftKommentar/debatForskningpeer review

  1. Memory T helper cells identify patients with nickel, cobalt, and chromium metal allergy

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Decrease of contact allergy to hydroxyisohexyl 3-cyclohexene carboxaldehyde in Europe prior to its ban and diagnostic value

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Epidermal T cell subsets-Effect of age and antigen exposure in humans and mice

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Contact dermatitis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • ESCD, EECDRG, EADV Contact Dermatitis Task Force, EAACI
Vis graf over relationer

BACKGROUND: In recent years, skin reactions secondary to the use of medical devices (MD), such as allergic contact dermatitis have increasingly been observed (e.g. to continuous blood sugar monitoring systems, insulin pumps, wound dressings, medical gloves, etc.): this is regarded as a developing epidemic. Lack of labelling of the composition of MD, as well as frequent lack of cooperation of manufacturers to disclose this relevant information, even when contacted by the clinician for the individual case of an established adverse reaction, significantly impede patient care.

OBJECTIVES: To advocate for full ingredient labelling in the implementation of EU regulation for MD.

METHODS: This position paper reviews the scientific literature, the current regulatory framework adopted for MD to date, and the likely impact, including some costs data in case of the absence of such labelling.

RESULTS: Efforts made by several scientific teams, who are trying to identify the culprit of such adverse effects, either via asking for cooperation from companies, or using costly chemical analyses of MD, can only partly, and with considerable delay, compensate for the absence of meaningful information on the composition of MD; hence, patient management is compromised. Indeed, without knowing the chemical substances present, physicians are unable to inform patients about which substances they should avoid, and which alternative MD may be suitable/tolerated.

CONCLUSION: There is an urgent need for full and accurate labelling of the chemical composition of MD in contact with the human body.

OriginalsprogEngelsk
TidsskriftJournal of the European Academy of Dermatology and Venereology : JEADV
Vol/bind35
Udgave nummer7
Sider (fra-til)1444-1448
Antal sider5
ISSN0926-9959
DOI
StatusUdgivet - jul. 2021

ID: 66835444